5月13日，继昨日大幅回调后，港药再度大涨，港股通创新药ETF（159570）涨近2%，成交额已超4亿元，盘中净流入3000万元。消息面上，美 签署有关降低美国处方药价格的行政令，行政令公布后，美大型药企股价直线拉升。分析指出，该行政令措辞模糊，几乎没有具体实施细节， 因此药企的股价反应积极，被解读为"没有预期的担忧那么大"。 港股通创新药ETF（159570）热门成分股多数飘红：荣昌生物涨超6%，百济神州涨超5%，信达生物涨超3%，康方生物、石药集团涨超1%，药 明生物微涨。 【行政令文本公布，对创新药影响几何？】 根据行政令文本，这项政策旨在将美国的处方药定价与"其他发达国家"进行对标，要求制药公司向美国市场提供"最惠国价格"。行政令强调， 即便算上药企折扣，美国支付的品牌药价格仍是其他经合组织国家支付价格的三倍以上。公告表示，"将建立一种机制，让美国患者能直接向 以'最惠国'价格向美国销售药品的制造商购买药品，绕过中间商。" 媒体评论认为，制药企业曾预料美高层会对药品价格采取行动，也对此感到担忧。而上述行政令力度看来远低于他们的预期。美股早盘时段， 大型药企股价迅速拉升，跌幅收窄并转涨，截至收盘，礼来、 ...

Group 1 - The China Securities Hong Kong Stock Connect Innovative Drug Index (931250) has seen a strong increase of 1.53% as of May 13, 2025, with notable gains from companies such as Rongchang Biopharmaceutical (09995) up 6.01%, BeiGene (06160) up 5.01%, and others [1] - The Hong Kong Innovative Drug 50 ETF (513780) opened higher by nearly 3% and is currently up 1.63%, indicating active market trading with a turnover of 20.57% and a transaction volume of 102 million yuan [1] - Over the past three months, the Hong Kong Innovative Drug 50 ETF has seen a significant growth in scale, increasing by 385 million yuan, making it the top fund in its category [1] Group 2 - Guotai Junan Securities states that the pharmaceutical sector's premium level relative to the entire A-share market is currently at a normal level, with a relative premium rate of 79.18% as of May 9, 2025 [2] - The ongoing listing of leading pharmaceutical company Heng Rui Medicine in the Hong Kong market is expected to enhance domestic and foreign investors' attention towards the domestic pharmaceutical industry, potentially catalyzing the innovative drug market [2] - The Hong Kong Innovative Drug 50 ETF (513780) closely tracks the China Securities Hong Kong Stock Connect Innovative Drug Index, selecting 50 companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [2]

截至2025年5月13日 09:39，恒生医疗保健指数(HSHCI)强势上涨1.38%，成分股百济神州(06160)上涨5.16%，医脉通(02192)上涨5.15%，乐普生物-B(02157)上 涨4.67%，信达生物(01801)，翰森制药(03692)等个股跟涨。恒生医疗ETF(513060)上涨1.72%，最新价报0.47元。流动性方面，恒生医疗ETF盘中换手 3.08%，成交3.05亿元。拉长时间看，截至5月12日，恒生医疗ETF近1月日均成交13.50亿元，排名可比基金第一。 德邦证券指出，AI的发展带动AI医疗的全面普及，大量医疗企业接入DS、华为等AI模型，开始摸索AI在医疗的应用。我们认为，1）拥有大量底层病人数据 的企业将有很大应用落地空间，2）拥有医保数据的企业有望深入应用AI，3）AI制药继续升级，建议关注此类公司。此外，积极关注1）创新药及其产业链 的技术革新与BD潜力；2）有业绩，基本面出现拐点的企业。 西南证券表示，2025年2月，国产大模型DeepSeek-R1全面开源与多领域适配，AI医疗迈入技术融合与行业重构的新阶段，DeepSeek的多模型协同能力成为 行业新范式。这种" ...

Core Viewpoint - The recent policy announced by Trump to align U.S. drug prices with the lowest global prices could lead to a significant decrease in prescription drug prices in the U.S., potentially by 30% to 80%, raising concerns among pharmaceutical companies, especially those exporting to the U.S. [1][2] Group 1: Market Performance - As of May 13, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 2.42%, with notable increases in stocks such as BeiGene (06160) up 4.15% and Innovent Biologics (01801) up 3.14% [1] - The Hong Kong Pharmaceutical ETF (159718) opened high and increased by 2.04%, with a latest price of 0.70 yuan, and a one-month cumulative increase of 3.32% [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) increased by 0.87%, with stocks like East China Pharmaceutical (000963) rising by 2.23% [4] Group 2: Trading Volume and Liquidity - The Hong Kong Pharmaceutical ETF had a turnover of 1.72% during the trading session, with a transaction volume of 4.0999 million yuan, and an average daily transaction volume of 95.7602 million yuan over the past month [1] - The latest scale of the Medical Innovation ETF (516820) reached 1.588 billion yuan [4] Group 3: Index Composition - The top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index accounted for 60.54% of the index, including BeiGene (06160) and WuXi Biologics (02269) [5] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represented 66.51% of the index, featuring companies like Hengrui Medicine (600276) and WuXi AppTec (603259) [8]

港股创新药板块反弹，百济神州涨近7%，荣昌生物、信达生物涨超4%，石药集团、康龙化成 （300759）、药明生物涨超1%。 ...

金融界2025年5月12日消息，中欧医疗创新股票A(006228) 最新净值1.1755元，下跌3.18%。该基金近1个 月收益率2.39%，同类排名515|702；近3个月收益率12.51%，同类排名26|701；今年来收益率13.05%， 同类排名48|696。 来源：金融界 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(20 ...

Core Points - The CSI Hong Kong Stock Connect Innovative Drug Index decreased by 3.3% to 706.45 points, with a trading volume of 17.018 billion yuan on May 12 [1] - Over the past month, the index has increased by 16.02%, 20.90% over the last three months, and 25.61% year-to-date [1] - The index consists of 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Index Composition - The top ten weighted companies in the index are: - Innovent Biologics (11.31%) - WuXi Biologics (10.96%) - BeiGene (9.29%) - CanSino Biologics (9.15%) - CSPC Pharmaceutical Group (7.19%) - China Biologic Products (6.94%) - Hansoh Pharmaceutical (4.18%) - WuXi AppTec (3.90%) - Zai Lab (3.88%) - 3SBio (3.45%) [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation [1] Industry Breakdown - The industry composition of the index includes: - Biopharmaceuticals: 46.61% - Chemical drugs: 30.42% - Pharmaceutical and biotechnology services: 21.65% - Medical commerce and services: 1.32% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential investment opportunities as the sector stabilizes [20]. 4. Blood Products - The report highlights the demand for immunoglobulin products and the potential for price increases due to supply shortages, recommending companies with strong product lines in this area [22]. 5. Vaccine Sector - The vaccine sector is currently under pressure, but there are opportunities in specific products that may gain market share, particularly in HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and operational capabilities in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD industry is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drug growth [37]. 9. Medical Services - Investment opportunities are identified in ophthalmology and dental services, with a focus on companies that can leverage consumer healthcare trends [42]. 10. Pharmacy Sector - The report indicates that leading pharmacy chains are stabilizing, and suggests focusing on companies with strong supply chain capabilities [45]. 11. Raw Materials - The raw materials sector is undergoing significant changes due to procurement policies, with recommendations for companies that can adapt to these shifts [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in medical devices and the ongoing trend of domestic replacements in various medical fields [51]. 13. Instrument Equipment - The scientific instrument sector is expected to recover as demand increases, with a focus on companies that are expanding their product offerings [56]. 14. Low-value Consumables - The report notes a potential recovery in the low-value consumables sector, particularly for companies that can capitalize on emerging market trends [59].

Core Viewpoint - The CSI Hong Kong Stock Connect Medical Theme Index has shown significant growth, with a 14.60% increase over the past month and a 17.07% increase year-to-date, reflecting strong performance in the medical sector within the Hong Kong stock market [1][2]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Medical Theme Index rose by 0.59% to 787.2 points, with a trading volume of 16.351 billion yuan [1]. - The index has increased by 10.23% over the past three months [1]. Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1]. - The top ten weighted stocks in the index include WuXi Biologics (16.41%), JD Health (10.86%), and Alibaba Health (7.38%) [1]. Group 3: Sector Allocation - The sector allocation of the index shows that medical services and commercial services account for 34.97%, while pharmaceuticals and biotechnology services account for 31.72% [2]. - Medical devices represent 12.28%, chemical drugs 10.50%, biological drugs 10.12%, and traditional Chinese medicine 0.42% of the index [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2].